Methscopolamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Methscopolamine
Accession Number
DB11315
Type
Small Molecule
Groups
Approved
Description

Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.

Structure
Thumb
Synonyms
  • Methylscopolamine
Product Ingredients
IngredientUNIICASInChI Key
Methscopolamine nitrateK0813KQM3V6106-46-3BSQIVYOSLFLSGE-RAFJPFSSSA-N
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Allergy DN IIMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1)KitBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31Us
Allergy DN IIMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1)KitBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31Us
Allergy DN PEMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31Us
Allergy DN PEMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitBreckenridge Pharmaceutical, Inc.2008-11-012010-03-31Us
AlleRx Dose PackMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (10 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)KitOralCornerstone Therapeutics Inc.2008-02-012012-10-31Us
AlleRx Dose PackMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (10 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)KitOralCornerstone Therapeutics Inc.2008-02-012012-10-31Us
AlleRx Dose Pack DFMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1)KitOralCornerstone Therapeutics Inc.2006-08-012012-10-31Us
AlleRx Dose Pack DFMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (4 mg/1) + Chlorpheniramine maleate (8 mg/1)KitOralCornerstone Therapeutics Inc.2006-08-012012-10-31Us
AlleRx Dose Pack PEMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitOralCornerstone Therapeutics Inc.2006-09-012012-10-31Us
AlleRx Dose Pack PEMethscopolamine nitrate (2.5 mg/1) + Methscopolamine nitrate (2.5 mg/1) + Chlorpheniramine maleate (8 mg/1) + Phenylephrine hydrochloride (40 mg/1) + Phenylephrine hydrochloride (10 mg/1)KitOralCornerstone Therapeutics Inc.2006-09-012012-10-31Us
Categories
UNII
VDR09VTQ8U
CAS number
13265-10-6
Weight
Average: 318.392
Monoisotopic: 318.169984677
Chemical Formula
C18H24NO4
InChI Key
LZCOQTDXKCNBEE-IKIFYQGPSA-N
InChI
InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12-,13-,14-,15+,16-,17+/m1/s1
IUPAC Name
(1R,2R,4S,5S,7S)-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium
SMILES
C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics

Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia [Dailymed].

Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1,10-PhenanthrolineThe therapeutic efficacy of Methscopolamine can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of Tachycardia can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Methscopolamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of Tachycardia can be increased when Methscopolamine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of Tachycardia can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Methscopolamine.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
AbediterolThe risk or severity of Tachycardia can be increased when Methscopolamine is combined with Abediterol.
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.
AcetaminophenThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Acetaminophen.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
71183
PubChem Substance
347827965
ChemSpider
21106347
BindingDB
50241132
ChEBI
135361
ChEMBL
CHEMBL376897
HET
3C0
Wikipedia
Methylscopolamine_bromide
ATC Codes
A03CB01 — Methylscopolamine and psycholepticsS01FA03 — MethylscopolamineA03BB03 — Methylscopolamine
PDB Entries
4u16 / 5yc8 / 5zk8 / 5zkc

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
KitOral
Tablet, chewableOral
Tablet, extended releaseOral
LiquidOral
TabletOral
SyrupOral
Tablet, multilayer, extended releaseOral
Kit
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0145 mg/mLALOGPS
logP-1.5ALOGPS
logP-3.3ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.06 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity95.63 m3·mol-1ChemAxon
Polarizability33.34 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Beta hydroxy acids and derivatives
Direct Parent
Beta hydroxy acids and derivatives
Alternative Parents
Benzene and substituted derivatives / Piperidines / Morpholines / N-alkylpyrrolidines / Tetraalkylammonium salts / Carboxylic acid esters / Azacyclic compounds / Oxacyclic compounds / Dialkyl ethers / Epoxides
show 7 more
Substituents
Beta-hydroxy acid / Monocyclic benzene moiety / Morpholine / Oxazinane / Piperidine / N-alkylpyrrolidine / Benzenoid / Tetraalkylammonium salt / Pyrrolidine / Quaternary ammonium salt
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on December 03, 2015 09:52 / Updated on May 01, 2019 13:14